Last reviewed · How we verify
NK042
At a glance
| Generic name | NK042 |
|---|---|
| Also known as | NKR-NK |
| Sponsor | Shanghai NK Cell Technology Co., LTD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis (PHASE1)
- A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors (PHASE1)
- A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NK042 CI brief — competitive landscape report
- NK042 updates RSS · CI watch RSS
- Shanghai NK Cell Technology Co., LTD portfolio CI